Sun Pharmaceuticals’ Absorica Received the US FDA’s Approval for Severe Recalcitrant Nodular Acne

 Sun Pharmaceuticals’ Absorica Received the US FDA’s Approval for Severe Recalcitrant Nodular Acne

Sun Pharma’s Ilumya Receives Australian Therapeutic Goods Administration (TGA) Approval for the Treatment of Moderate-to-Severe Plaque Psoriasis

Shots:

  • The approval is based on the study assessing of Absorica vs another isotretinoin 925 patients aged 12 years and older in patients with severe recalcitrant nodular acne
  • Study results: Mean reduction in nodular lesions (-15.68 vs -15.62); 90% reduction in total nodular lesion count (70% vs 75%)
  • Absorica ((isotretinoin) is a prescription medicine granted patients aged 12 years of age and older treat the most severe form of acne nodular acne and also have a boxed warning for embryo-fetal toxicity – contraindicated in pregnancy

Click here to­ read full press release/ article | Ref: Optumrx | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post